


AltheaDx Express Pathway: Biomarkers for Cisplatin Resistance

- ▶ Cisplatin-resistant patients have a genetically advanced form of cancer and are unlikely to benefit from cytotoxic therapy. Analysis of resistance can provide information to:

- Select patients for inclusion/exclusion into clinical trials
- Retrospectively evaluate differential patient responses
- Customize patient treatment in tumor types where cisplatin is generally used
- Prioritize potential secondary and tertiary indications
- Aid/guide development of early stage oncology programs



AltheaDx's multivariate molecular biomarker discovery system provides:

- Broad RNA expression profiles using microarrays
- Quantification of defined gene sets *via* quantitative XP-PCR
- DNA genotypes identify key mutations and SNPs

AltheaDx has developed gene expression tests to monitor platinum response, resistance, and toxicity:

NCI Marker Set

Genes differentially responsive in resistant and sensitive patients

Public Marker Set

Genes associated with resistance and/or mechanism of action


ADME-Toxicity Set

Genes that predict kidney toxicity, drug inactivation/metabolism

Novel Biomarkers

AltheaDx is seeking partnerships to develop customized gene sets

NCI Marker Set Patient Profiles



Bonome, et.al. ASCO 2007

AltheaDx harnesses the power of molecular biomarkers to support:

- Disease Staging/Subtyping
- Predictive Drug Response
- Toxicity Profiling
- Diagnosis and Monitoring
- Prognosis and Enrichment
- Lead Optimization